Prospective Follow-up of Relapse Myeloma Patients After Previous Exposure to Bortezomib and Lenalidomide Treated on Pomalidomide and Dexamethasone
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors National University Hospital (Singapore)
- 20 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2016 Interim results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (data cut-off date of 30 April 2016)
- 06 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.